Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
503.42
-3.32 (-0.66%)
Oct 2, 2026, 12:36 PM EDT - Market open
Vertex Pharmaceuticals Market Cap
Vertex Pharmaceuticals has a market cap or net worth of $127.6 billion as of October 2, 2026. Its market cap has increased by 23.12% in one year.
Market Cap
127.60B
Enterprise Value
115.93B
1-Year Change
23.12%
Ranking
Category
Stock Price
$503.42
ChartMarket Cap Chart
Since December 1, 1998, Vertex Pharmaceuticals's market cap has increased from $611.50M to $127.60B, an increase of 20,766.28%. That is a compound annual growth rate of 21.13%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 2, 2026 | 127.60B | 10.93% |
| Dec 31, 2025 | 115.03B | 10.91% |
| Dec 31, 2024 | 103.71B | -1.09% |
| Dec 29, 2023 | 104.85B | 41.44% |
| Dec 30, 2022 | 74.13B | 32.76% |
| Dec 31, 2021 | 55.83B | -9.15% |
| Dec 31, 2020 | 61.46B | 9.15% |
| Dec 31, 2019 | 56.30B | 32.95% |
| Dec 31, 2018 | 42.35B | 11.74% |
| Dec 29, 2017 | 37.90B | 107.41% |
| Dec 30, 2016 | 18.27B | -40.90% |
| Dec 31, 2015 | 30.92B | 8.21% |
| Dec 31, 2014 | 28.57B | 64.52% |
| Dec 31, 2013 | 17.37B | 91.17% |
| Dec 31, 2012 | 9.09B | 31.16% |
| Dec 30, 2011 | 6.93B | -2.69% |
| Dec 31, 2010 | 7.12B | -8.32% |
| Dec 31, 2009 | 7.76B | 69.85% |
| Dec 31, 2008 | 4.57B | 48.74% |
| Dec 31, 2007 | 3.07B | -34.61% |
| Dec 29, 2006 | 4.70B | 71.34% |
| Dec 30, 2005 | 2.74B | 223.10% |
| Dec 31, 2004 | 848.90M | 5.56% |
| Dec 31, 2003 | 804.20M | -33.56% |
| Dec 31, 2002 | 1.21B | -34.33% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Moderna | 75.67B |
| Regeneron Pharmaceuticals | 73.05B |
| argenx SE | 59.26B |
| Revolution Medicines | 44.35B |
| BeOne Medicines AG | 40.01B |
| Royalty Pharma | 33.04B |
| Alnylam Pharmaceuticals | 29.77B |
| Roivant Sciences | 25.74B |